Drug Profile
H 101
Alternative Names: H-101; Oncorine; rAd5 H101Latest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator Shanghai Sunway Biotech
- Developer Shanghai Pharmaceuticals Holding; Shanghai Sunway Biotech
- Class Antineoplastics; Oncolytic viruses
- Mechanism of Action P53 gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Head and neck cancer
- Preclinical Malignant ascites
- Discontinued Bone cancer; Liver cancer; Lung cancer; Malignant pleural effusion; Pancreatic cancer; Peritoneal cancer
Most Recent Events
- 24 Aug 2023 Preclinical trials in Malignant ascites in China (Intratumoural), prior to August 2023 (Shanghai Pharmaceuticals Holding pipeline, August 2023)
- 05 Dec 2017 Discontinued - Clinical-Phase-Unknown for Liver cancer in China (Intratumoural)
- 05 Dec 2017 Discontinued - Clinical-Phase-Unknown for Malignant pleural effusion in China (Intratumoural)